Amine substituted N-(1H-benzimidazol-2ylmethyl)-5,6,7,8-tetrahydro-8-quinolinamines as CXCR4 antagonists with potent activity against HIV-1

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 17, 2009, Pages 5048-5052

  Gudmundsson, Kristjan S ^a   Sebahar, Paul R ^a   Richardson, Leah D'Aurora ^a   Miller, John F ^a   Turner, Elizabeth M ^a   Catalano, John G ^a   Spaltenstein, Andrew ^a   Lawrence, Wendell ^a   Thomson, Michael ^a   Jenkinson, Stephen ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

8 [(4 AMINOBUTYL)(2 BENZIMIDAZOLYLMETHYL)AMINO] 1,2,3,4 TETRAHYDROQUINOLINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; KRH 1636; N (1H BENZIMIDAZOL 2 YLMETHYL) 5,6,7,8 TETRAHYDRO 8 QUINOLINAMINE DERIVATIVE; PLERIXAFOR; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; DRUG ACTIVITY; DRUG POTENCY; DRUG SUBSTITUTION; DRUG SYNTHESIS; HUMAN IMMUNODEFICIENCY VIRUS 1; IC 50; NONHUMAN;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AMINES; ANTI-HIV AGENTS; BENZIMIDAZOLES; CELL LINE, TUMOR; HETEROCYCLIC COMPOUNDS, 1-RING; HIV-1; HUMANS; RECEPTORS, CXCR4;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 68349150601     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.07.037     Document Type: Article

References (24)

1. Berson J.F., Long D., Doranz B.J., Rucker J., Jirik F.R., and Doms R.W. J. Virol. 70 (1996) 6288
2. Buckley C.D., Amft N., Bradfield P.F., Pilling D., Ross E., Arenzana-Seisdedos F., Amara A., Curnow S.J., Lord J.M., Scheel-Toellner D., and Salmon M. J. Immunol. 165 (2000) 3423
3. Ma Q., Jones D., and Springer T.A. Immunity 10 (1999) 463
4. Zlotnik A. Int. J. Cancer 119 (2006) 2026
5. Burger J.A., and Kipps T.J. Blood 107 (2006) 1761
6. Shaheen F., and Collman R.G. Curr. Opin. Infect. Dis. 17 (2004) 7
7. Schuitemaker H., Koot M., Kootstra N.A., Dercksen M.W., de Goede R.E., van Steenwijk R.P., Lange J.M., Schattenkerk J.K., Miedema F., and Tersmette M. J. Virol. 66 (1992) 1354
8. Hendrix C.W., Flexner C., MacFarland R.T., Giandomenico C., Fuchs E.J., Redpath E., Bridger G., and Henson G.W. Antimicrob. Agents Chemother. 44 (2000) 1667
9. Matthys P., Hatse S., Vermeire K., Wuyts A., Bridger G., Henson G.W., De Clercq E., Billiau A., and Schols D. J. Immunol. 167 (2001) 4686
10. Tamamura H., Fujisawa M., Hiramatsu K., Mizumoto M., Nakashima H., Yamamoto N., Otaka A., and Fujii N. FEBS Lett. 569 (2004) 99
11. Sumner-Smith M., Zheng Y., Zhang Y.P., Twist E.M., and Climie S.C. Drugs Exp. Clin. Res. 21 (1995) 1
12. NCI Cancer Bulletin April 26, 2005, 17, 4.
13. Fujii N., Oishi S., Hiramatsu K., Araki T., Ueda S., Tamamura H., Otaka A., Kusano S., Terakubo S., Nakashima H., Broach J.A., Trent J.O., Wang Z., and Peiper S.C. Angew. Chem. Int. Ed. 42 (2003) 3251
14. DeMarco S.J., Henze H., Lederer A., Moehle K., Maukharejee R., and Romagnoli B. Bioorg. Med. Chem. 14 (2006) 8396
15. Ichiyama K., Yokoyama-Kumakura S., Tanaka Y., Tanaka R., Hirose K., Bannai K., Edamatsu T., Yanaka M., Niitani Y., Miyano-Kurosaki N., Takaku H., Koyanagi Y., and Yamamoto N. Proc. Natl. Acad. Sci. U.S.A. 100 (2003) 4185
16. De Clercq E. Nat. Rev. Drug Disc. 2 (2003) 581
17. Bridger, G.; Skerlj, R.; Kaller, A.; Harwig, C.; Bogucki, D.; Wilson, T. R.; Crawford, J.; McEachern, E. J.; Atsma, B.; Nan, S.; Zhou, Y.; Schols, D.; Smith, C. D.; DiFluri, R. M. WO Patent 2003/055876.
18. Crawford, J. B.; Zhu, Y.; Chen, G.; Baird, I. R.; Skerlj, R. WO Patent 2006/039250.
19. Crawford J.B., Chen G., Gauthier D., Wilson T., Carpenter B., Baird I.R., McEachern E., Kaller A., Harwig C., Atsma B., Skerlj R.T., and Bridger G.J. Org. Process Res. Dev. 12 (2008) 823
20. Stone N., Dunaway S.B., Flexner C., Tierney C., Calandra G.B., Becker S., Cao Y.-L., Wiggins I.P., Conley J., MacFarland R.T., Park J.-G., Lalama C., Snyder S., Kallungal B., Klingman K.L., and Hendrix C.W. Antimirob. Agents Chemother. 51 (2007) 2351
21. Kelly T.R., and Lebedev R.L. J. Org. Chem. 67 (2002) 2197
22. Tetrahydroquinolone 3 is commercially available.
23. McEachern, E. J.; Bridger, G. J.; Skupinska, K. A.; Skerlj, R. T. WO Patent 2003/022785.
24. All compounds were also characterized pharmacologically in a cell based functional assay and shown to be non-competitive antagonists of the CXCR4 receptor.